Parenteral Administration of Capsule Depolymerase EnvD Prevents Lethal Inhalation Anthrax Infection
Open Access
- 1 December 2015
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (12) , 7687-7692
Abstract
Left untreated, inhalation anthrax is usually fatal. Vegetative forms of Bacillus anthracis survive in blood and tissues during infection due to elaboration of a protective poly-γ-d-glutamic acid (PDGA) capsule that permits uncontrolled bacterial growth in vivo, eventually leading to overwhelming bacillosis and death. As a measure to counter threats from multidrug-resistant strains, we are evaluating the prophylactic and therapeutic potential of the PDGA depolymerase EnvD, a stable and potent enzyme which rapidly and selectively removes the capsule from the surface of vegetative cells. Repeated intravenous administration of 10 mg/kg recombinant EnvD (rEnvD) to mice infected with lethal doses of B. anthracis Ames spores by inhalation prevented the emergence of symptoms of anthrax and death; all animals survived the 5-day treatment period, and 70% survived to the end of the 14-day observation period. In contrast to results in sham-treated animals, the lungs and spleen of rEnvD-dosed animals were free of gross pathological changes. We conclude that rEnvD has potential as an agent to prevent the emergence of inhalation anthrax in infected animals and is likely to be effective against drug-resistant forms of the pathogen.Keywords
This publication has 24 references indexed in Scilit:
- Draft Genome Sequences of Pseudomonas fluorescens BS2 and Pusillimonas noertemannii BS8, Soil Bacteria That Cooperate To Degrade the Poly-γ- d -Glutamic Acid Anthrax CapsuleMicrobiology Resource Announcements, 2013
- Animal models of human anthrax: The Quest for the Holy GrailMolecular Aspects of Medicine, 2009
- Treatment of Experimental Anthrax with Recombinant Capsule DepolymeraseAntimicrobial Agents and Chemotherapy, 2008
- Poly-γ-Glutamate Capsule-Degrading Enzyme Treatment Enhances Phagocytosis and Killing of EncapsulatedBacillus anthracisAntimicrobial Agents and Chemotherapy, 2007
- Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymeraseJournal of Antimicrobial Chemotherapy, 2005
- Prevention and Cure of Systemic Escherichia coli K1 Infection by Modification of the Bacterial PhenotypeAntimicrobial Agents and Chemotherapy, 2004
- AnthraxAnnual Review of Microbiology, 2001
- EXPERIMENTAL TYPE III PNEUMOCOCCUS PNEUMONIA IN MONKEYSJournal of Experimental Medicine, 1934
- THE ACTION OF A SPECIFIC ENZYME UPON THE DERMAL INFECTION OF RABBITS WITH TYPE III PNEUMOCOCCUSJournal of Experimental Medicine, 1932
- DECOMPOSITION OF THE CAPSULAR POLYSACCHARIDE OF PNEUMOCOCCUS TYPE III BY A BACTERIAL ENZYMEJournal of Experimental Medicine, 1931